Cargando…
Chenodeoxycholic acid rescues axonal degeneration in induced pluripotent stem cell-derived neurons from spastic paraplegia type 5 and cerebrotendinous xanthomatosis patients
BACKGROUND: Biallelic mutations in CYP27A1 and CYP7B1, two critical genes regulating cholesterol and bile acid metabolism, cause cerebrotendinous xanthomatosis (CTX) and hereditary spastic paraplegia type 5 (SPG5), respectively. These rare diseases are characterized by progressive degeneration of co...
Autores principales: | Mou, Yongchao, Nandi, Ghata, Mukte, Sukhada, Chai, Eric, Chen, Zhenyu, Nielsen, Jorgen E., Nielsen, Troels T., Criscuolo, Chiara, Blackstone, Craig, Fraidakis, Matthew J., Li, Xue-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080795/ https://www.ncbi.nlm.nih.gov/pubmed/37024986 http://dx.doi.org/10.1186/s13023-023-02666-w |
Ejemplares similares
-
Psychiatric manifestations in cerebrotendinous xanthomatosis
por: Fraidakis, M J
Publicado: (2013) -
Cerebrotendinous xanthomatosis‐associated diarrhea and response to chenodeoxycholic acid treatment
por: Brass, Eric P., et al.
Publicado: (2020) -
Cerebrotendinous Xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid
por: Islam, Mahjabin, et al.
Publicado: (2021) -
Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment
por: Huidekoper, Hidde H., et al.
Publicado: (2015) -
Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis
por: Zübarioğlu, Tanyel, et al.
Publicado: (2019)